Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems
- Mitja Jevnikar1,2,3,
- David Montani1,2,3,
- Laurent Savale1,2,3,
- Andrei Seferian1,2,3,
- Etienne-Marie Jutant1,2,3,
- Athénaïs Boucly1,2,3,
- Mariana Preda1,2,3,
- Jason Weatherald4,5,
- Sophie Bulifon1,2,3,
- Florence Parent1,2,3,
- Philippe Brenot1,2,6,
- Elie Fadel1,2,7,
- Olivier Sitbon1,2,3,
- Gérald Simonneau1,2,3,
- Marc Humbert1,2,3,8 and
- Xavier Jaïs1,2,3,8⇑
- 1Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
- 2INSERM UMR_S 999, «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, Le Plessis-Robinson, France
- 3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- 4Department of Medicine, Division of Respirology, University of Calgary, Calgary, AB, Canada
- 5Libin Cardiovascular Institute, Calgary, AB, Canada
- 6Department of Radiology, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
- 7Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
- 8These authors contributed equally
- Correspondance: Xavier Jaïs, MD, Service de pneumologie, Le Kremlin-Bicêtre, France, 78 rue du général Leclerc, 94270 Le Kremlin Bicêtre, France. E-mail: xavier.jais{at}gmail.com
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Jevnikar has nothing to disclose.
Conflict of interest: Pr. Montani reports grants and personal fees from Actelion, personal fees from GSK, personal fees from MSD, grants from Bayer, outside the submitted work.
Conflict of interest: Dr. Savale reports grants and personal fees from Actelion, personal fees from GSK, personal fees from MSD, grants from Bayer, outside the submitted work.
Conflict of interest: Dr. Seferian has nothing to disclose.
Conflict of interest: Dr. Jutant has nothing to disclose.
Conflict of interest: Dr. Boucly has nothing to disclose.
Conflict of interest: Dr. Preda has nothing to disclose.
Conflict of interest: Dr. Weatherald reports grants, personal fees and non-financial support from Janssen Inc., grants, personal fees and non-financial support from Actelion, personal fees and non-financial support from Bayer, personal fees from Novartis, outside the submitted work.
Conflict of interest: Dr. Bulifon has nothing to disclose.
Conflict of interest: Dr. Parent has nothing to disclose.
Conflict of interest: Dr. Brenot has nothing to disclose.
Conflict of interest: Pr. Fadel has nothing to disclose.
Conflict of interest: Pr. Sitbon reports grants and personal fees from Actelion, personal fees from GSK, personal fees from MSD, grants from Bayer, outside the submitted work.
Conflict of interest: Pr. Simonneau reports grants and personal fees from Actelion, personal fees from GSK, personal fees from MSD, grants from Bayer, outside the submitted work.
Conflict of interest: Dr. Humbert reports grants and personal fees from Actelion, personal fees from GSK, personal fees from Merck, outside the submitted work.
Conflict of interest: Dr. Jaïs reports grants and personal fees from Actelion, personal fees from GSK, personal fees from MSD, grants from Bayer, outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received June 7, 2020.
- Accepted July 9, 2020.
- Copyright ©ERS 2020